Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2007-11-09
2010-06-15
Mertz, Prema (Department: 1646)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007200, C435S007210
Reexamination Certificate
active
07736860
ABSTRACT:
Described are methods and compositions that inhibit IL-1 signalling for the treatment of acute inflammatory response to cell necrosis, and the attendant collateral tissue damage.
REFERENCES:
patent: 5856099 (1999-01-01), Miraglia et al.
patent: 6471961 (2002-10-01), Tobinik
patent: 6989244 (2006-01-01), Tsuchiya et al.
patent: 7033830 (2006-04-01), Karras et al.
patent: 7115402 (2006-10-01), Feder et al.
patent: 2006/0276458 (2006-12-01), Chiou
Abraham, “Neutrophils and acute lung injury,”Crit. Care Med., 31:S195-S199 (2003).
Adachi et al., “Targeted disruption of the MyD88 gene results in loss of IL-1- and IL-18-mediated function,”Immunity, 9:143-150 (1998).
Beck et al., “Generation of soluble interleukin-1 receptor from an immunoadhesin by specific cleavage,”Mol. Immunol. 31(17):1335-1344 (1994).
Bless et al., “Protective effects of an aptamer inhibitor of neutrophil elastase in lung inflammatory injury,”Curr. Biol., 7:877-880 (1997).
Braddock and Quinn, “Targeting IL-1 in inflammatory disease: new opportunities for therapeutic intervention,”Nat. Rev. 3:1-10 (2004).
Burch and Mahan, “Oligonucleotides antisense to the interleukin 1 receptor mRNA block the effects of interleukin 1 in cultured murine and human fibroblasts and in mice,”J. Clin. Invest. 88(4):1190-1196 (1991).
Chen et al., “Neutrophil-derived leukotriene B4 is required for inflammatory arthritis,”J. Exp. Med., 203:837-842 (2006).
Dawson et al., “Effects of soluble interleukin-1 type II receptor on rabbit antigen-induced arthritis: clinical, biochemical and histological assessment,”Rheumatology, 38(5):401-406 (1999).
Fadok et al., “Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF,”J. Clin. Invest., 101:890-898 (1998).
Fisher and Meiselmann, “Polymorphonuclear leukocytes in ischemic vascular disease,”Thromb. Res., 74(Suppl. 1):S21-S34 (1994).
Fredericks et al., “Identification of potent human anti-IL-1RI antagonist antibodies,”Protein Eng. Des. Sel., 17(1):95-106 (2004).
Hemmi et al., “A Toll-like receptor recognizes bacterial DNA,”Nature, 408:740-745 (2000).
Hemmi et al., “Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway,”Nat. Immunol., 3:196-200 (2002).
Huynh et al., “Phosphatidylserine-dependent ingestion of apoptotic cells promotes TGF-beta1 secretion and the resolution of inflammation,”J. Clin. Invest., 109:41-50 (2002).
Jaeschke, “Mechanisms of Liver Injury. II. Mechanisms of neutrophil-induced liver cell injury during hepatic ischemia-reperfusion and other acute inflammatory conditions,”Am. J. Physiol. Gastrointest. Liver Physiol., 290:G1083-G1088 (2006).
Kim et al., “A unique requirement for the leukotriene B4 receptor BLT1 for neutrophil recruitment in inflammatory arthritis,”J. Exp. Med., 203:829-835 (2006).
Li et al., “An essential role of the NF-kappa B/Toll-like receptor pathway in induction of inflammatory and tissue-repair gene expression by necrotic cells,”J. Immunol., 166:7128-7135 2001.
Liu et al., “Neutrophil depletion protects against murine acetaminophen hepatotoxicity,”Hepatology, 43:1220-1230 (2006).
Majno et al., “Cellular death and necrosis: chemical, physical and morphologic changes in rat liver,”Virchows Arch. Pathol. Anat. Physiol. Klin. Med., 333:421-465 (1960).
Randle et al., “ICE/Caspase-1 inhibitors as novel anti-inflammatory drugs,”Exp. Op. Inv. Drugs, 10(7):1207-1209 (2001).
Sadasivan et al., “Neutrophil mediated microvascular injury in acute, experimental compartment syndrome,”Clin. Orthop. Relat. Res., 206-2150 (1997).
Sawa et al., “Leukocyte depletion attenuates reperfusion injury in patients with left ventricular hypertrophy,”Circulation, 93:1640-1646 (1996).
Scaffidi, “Release of chromatin protein HMGB1 by necrotic cells triggers inflammation,”Nature, 418:191-195 (2002).
Sekido et al., “Prevention of lung reperfusion injury in rabbits by a monoclonal antibody against interleukin-8,”Nature, 365:654-657 (1993).
Serhan et al., “Resolution of inflammation: the beginning programs the end,”Nat. Immunol., 6:1191-1197 (2005).
Shimizu et al., “Involvement of a NF-kappa B-like transcription factor in the activation of the interleukin-6 gene by inflammatory lymphokines,”Mol. Cell. Biol., 10(2):561-568 (1990).
Symons et al., “Purification and characterization of a novel soluble receptor for interleukin 1,”J. Exp. Med., 174(5):1251-1254 (1991).
Symons et al., “Soluble type II interleukin 1 (IL-1) receptor binds and blocks processing of IL-1 beta precursor and loses affinity for IL-1 receptor antagonist,”Proc. Natl. Acad. Sci. U. S. A., 92(5):1714-1718 (1995).
Takeuchi et al., “Cutting edge: role of Toll-like receptor 1 in mediating immune response to microbial lipoproteins,”J. Immunol., 169:10-14 (2002).
Takeuchi et al., “Differential roles of TLR2 and TLR4 in recognition of gram-negative and gram-positive bacterial cell wall components,”Immunity, 11:443-451 (1999).
Takeuchi et al., “Discrimination of bacterial lipoproteins by Toll-like receptor 6,”Int. Immunol., 13:933-940 (2001).
Valentino et al., “First clinical trial of a novel caspase inhibitor: anti-apoptotic caspase inhibitor, IDN-6556, improves liver enzymes,”Int. J. Clin. Pharmacol. Ther., 41(10):441-449 (2003).
Vickers et al., “Modification of MyD88 mRNA splicing and inhibition of IL-1beta signaling in cell culture and in mice with a 2′-O-methoxyethyl-modified oligonucleotide,”J. Immunol., 176(6):3652-3661 (2006).
Watson et al., “The IL-1 -converting enzyme (caspase-1) inhibits apoptosis of inflammatory neutrophils through activation of IL-1 ,”J. Immunol., 161:957-1962 (1998).
Wipke et al., “Essential role of neutrophils in the initiation and progression of a murine model of rheumatoid arthritis,”J. Immunol., 167:1601-1608 (2001).
Yamamoto et al, “Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway,”Science, 301:640-643 (2003).
Yamamoto et al, “TRAM is specifically involved in the Toll-like receptor 4-mediated MyD88-independent signaling pathway,”Nat. Immunol., 4:1144-1150 (2003).
Yamamoto et al.,. “Essential role for TIRAP in activation of the signalling cascade shared by TLR2 and TLR4,”Nature, 420:324-329 (2002).
Zhang et al., “A toll-like receptor that prevents infection by uropathogenic bacteria,”Science, 303:1522-1526 (2004).
Zingarelli et al., “Blockade of Poly(ADP-ribose) synthetase inhibits neutrophil recruitment, oxidant generation, and mucosal injury in murine colitis,”Gastroenterology, 116:335-345 (1999).
Chen Chun-Jen
Rock Kenneth L.
Fish & Richardson P.C.
Mertz Prema
Univeristy of Massachusetts
LandOfFree
Methods of identifying compounds for the treatment of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Methods of identifying compounds for the treatment of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Methods of identifying compounds for the treatment of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4241600